A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.
复制标题

一种棕榈酸结合的肽基泛冠状病毒融合抑制剂有效抑制SARS-CoV-2 Omicron和其他相关变体的感染。

DOI:
10.3390/v14030549
复制
发表时间:
2022-03-06
期刊:
Viruses
影响因子:
--
通讯作者:
Wang Q
Wang Q
中科院分区:
其他
文献类型:
--
作者:
Lan Q;Chan JF;Xu W;Wang L;Jiao F;Zhang G;Pu J;Zhou J;Xia S;Lu L;Yuen KY;Jiang S;Wang Q

文献摘要

参考文献

被引文献

相似文献

我们之前的研究表明,胆固醇偶联的、基于肽的泛冠状病毒(CoV)融合抑制剂可以有效抑制人类冠状病毒感染。然而,目前临床只测试了基于棕榈酸(C16)的脂肽药物,这表明开发基于C16的脂肽药物是可行的。本研究设计并合成了一种c16修饰的泛cov融合抑制剂EK1-C16,发现其能有效抑制SARS-CoV-2及其关注变异(VOCs),包括Omicron,以及其他人类和蝙蝠sars相关cov (sarsr - cov)的感染。这些结果表明,EK1-C16可以进一步开发用于临床,以预防和治疗当前流行的MERS-CoV、SARS-CoV-2及其挥发性有机化合物,以及未来任何新出现或再出现的冠状病毒的感染。
Our previous studies have shown that cholesterol-conjugated, peptide-based pan-coronavirus (CoV) fusion inhibitors can potently inhibit human CoV infection. However, only palmitic acid (C16)-based lipopeptide drugs have been tested clinically, suggesting that the development of C16-based lipopeptide drugs is feasible. Here, we designed and synthesized a C16-modified pan-CoV fusion inhibitor, EK1-C16, and found that it potently inhibited infection by SARS-CoV-2 and its variants of concern (VOCs), including Omicron, and other human CoVs and bat SARS-related CoVs (SARSr-CoVs). These results suggest that EK1-C16 could be further developed for clinical use to prevent and treat infection by the currently circulating MERS-CoV, SARS-CoV-2 and its VOCs, as well as any future emerging or re-emerging coronaviruses.
DOI: 10.1128/jvi.02165-20
发表时间: 2021-04-12
影响因子: 5.4
作者:
Lévy Y;Lacabaratz C;Lhomme E;Wiedemann A;Bauduin C;Fenwick C;Foucat E;Surenaud M;Guillaumat L;Boilet V;Rieux V;Bouchaud O;Girard PM;Molina JM;Morlat P;Hocqueloux L;Richert L;Pantaleo G;Lelièvre JD;Thiébaut R
通讯作者: Thiébaut R
DOI: 10.1038/nrmicro.2016.81
发表时间: 2016-08
期刊: Nature reviews. Microbiology
影响因子: --
作者:
de Wit E;van Doremalen N;Falzarano D;Munster VJ
通讯作者: Munster VJ
DOI: 10.3390/ijms222111869
发表时间: 2021-11-01
影响因子: 5.6
作者:
Lan Q;Wang C;Zhou J;Wang L;Jiao F;Zhang Y;Cai Y;Lu L;Xia S;Jiang S
通讯作者: Jiang S
DOI: 10.2991/jegh.k.201105.001
发表时间: 2021-06
影响因子: 7.3
作者:
Sajini AA;Alkayyal AA;Mubaraki FA
通讯作者: Mubaraki FA
DOI: 10.1038/nrmicro2090
发表时间: 2009-03
期刊: Nature reviews. Microbiology
影响因子: --
作者:
通讯作者: --